The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate-or higer-risk myelodysplastic syndromes in the elderly patients / 中华内科杂志
Chinese Journal of Internal Medicine
;
(12): 606-609, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-611209
ABSTRACT
To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine regimen in patients with acute myeloid leukemia (AML) and intermediate-or higer-risk myelodysplastic syndrome (MDS).Of 6 AML cases,2 achieved complete remission (CR),2 with partial remission(PR),1 with stable disease(SD),1 with progressive disease(PD).As to the 8 MDS patients,one achieved CR and 6 with hematologic improvement (HI),1 case SD.Low dose subcutaneous decitabine regimen could be an alternative choice of older AML or MDS patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo de etiologia
Idioma:
Chinês
Revista:
Chinese Journal of Internal Medicine
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS